Baricitinib Liposomes as a New Approach for the Treatment of Sjögren's Syndrome
Sjögren's syndrome is a chronic systemic autoimmune disease affecting from 0.2 to 3% of the general population. The current treatment for Sjögren's syndrome is aimed at controlling symptoms such as dry eyes and xerostomia. Systemic therapy with glucocorticoids or immunosuppressants is also...
| Autores: | , , , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Estado: | Versão publicada |
| Data de publicação: | 2022 |
| País: | España |
| Recursos: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositório: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:2445/191490 |
| Acesso em linha: | https://hdl.handle.net/2445/191490 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Síndrome de Sjögren Liposomes Sistemes d'alliberament de medicaments Oftalmologia Sjogren's syndrome Drug delivery systems Ophthalmology |
| id |
ES_a7e33c17f3b4ad7c2661d8d001efab96 |
|---|---|
| oai_identifier_str |
oai:recercat.cat:2445/191490 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Baricitinib Liposomes as a New Approach for the Treatment of Sjögren's SyndromeGarrós, NúriaMallandrich Miret, MireiaBeirampour, NegarMohammadi-Meyabadi, RoyaDomènech Cabrera, ÒscarRodríguez Lagunas, María JoséClares Naveros, BeatrizColom Codina, HelenaSíndrome de SjögrenLiposomesSistemes d'alliberament de medicamentsOftalmologiaSjogren's syndromeLiposomesDrug delivery systemsOphthalmologySjögren's syndrome is a chronic systemic autoimmune disease affecting from 0.2 to 3% of the general population. The current treatment for Sjögren's syndrome is aimed at controlling symptoms such as dry eyes and xerostomia. Systemic therapy with glucocorticoids or immunosuppressants is also used. Baricitinib is an immunosuppressant drug, specifically a Janus kinases 1 and 2 selective inhibitor. We propose ocular liposomal formulations loaded with baricitinib for the management of Sjögren's syndrome. The novelty of the work relies on the fact that, for the first time, baricitinib is intended to be used for topical delivery. Two liposomal formulations were prepared with different lipids: (i) L-α-phosphatidylcholine (Lα-PC) and (ii) a combination of lipids 1-palmitoyl-2-oleoyl-phosphatidylethanolamine: s1-Palmitoyl-2-oleoyl-sn-glycerol-3-phosphoglycerol (3:1, mol/mol) (POPE:POPG), and they were physicochemically characterized. The in vitro drug release and the ex vivo permeation through corneal and scleral tissues were also assessed. Finally, the tolerance of the formulations on the ocular tissues was evaluated by the HET-CAM technique, as well as through the histological analysis of the cornea and sclera and the cornea transparency. Both liposomes resulted in small, spherical shapes, with suitable physicochemical properties for the ocular administration. Lα-PC led to higher flux, permeation, and retention in the sclera, whereas POPE:POPG led to higher flux and permeation in the cornea. The formulations showed no irritant effects on the chorioallantoic membrane. Additionally, the liposomes did not affect the cornea transparency when they were applied, and the histological analysis did not reveal any structural alterationMDPI2022202220222022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/191490Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics14091895Pharmaceutics, 2022https://doi.org/10.3390/pharmaceutics14091895cc-by (c) Garrós, Núria et al., 2022https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1914902026-05-29T05:05:01Z |
| dc.title.none.fl_str_mv |
Baricitinib Liposomes as a New Approach for the Treatment of Sjögren's Syndrome |
| title |
Baricitinib Liposomes as a New Approach for the Treatment of Sjögren's Syndrome |
| spellingShingle |
Baricitinib Liposomes as a New Approach for the Treatment of Sjögren's Syndrome Garrós, Núria Síndrome de Sjögren Liposomes Sistemes d'alliberament de medicaments Oftalmologia Sjogren's syndrome Liposomes Drug delivery systems Ophthalmology |
| title_short |
Baricitinib Liposomes as a New Approach for the Treatment of Sjögren's Syndrome |
| title_full |
Baricitinib Liposomes as a New Approach for the Treatment of Sjögren's Syndrome |
| title_fullStr |
Baricitinib Liposomes as a New Approach for the Treatment of Sjögren's Syndrome |
| title_full_unstemmed |
Baricitinib Liposomes as a New Approach for the Treatment of Sjögren's Syndrome |
| title_sort |
Baricitinib Liposomes as a New Approach for the Treatment of Sjögren's Syndrome |
| dc.creator.none.fl_str_mv |
Garrós, Núria Mallandrich Miret, Mireia Beirampour, Negar Mohammadi-Meyabadi, Roya Domènech Cabrera, Òscar Rodríguez Lagunas, María José Clares Naveros, Beatriz Colom Codina, Helena |
| author |
Garrós, Núria |
| author_facet |
Garrós, Núria Mallandrich Miret, Mireia Beirampour, Negar Mohammadi-Meyabadi, Roya Domènech Cabrera, Òscar Rodríguez Lagunas, María José Clares Naveros, Beatriz Colom Codina, Helena |
| author_role |
author |
| author2 |
Mallandrich Miret, Mireia Beirampour, Negar Mohammadi-Meyabadi, Roya Domènech Cabrera, Òscar Rodríguez Lagunas, María José Clares Naveros, Beatriz Colom Codina, Helena |
| author2_role |
author author author author author author author |
| dc.subject.none.fl_str_mv |
Síndrome de Sjögren Liposomes Sistemes d'alliberament de medicaments Oftalmologia Sjogren's syndrome Liposomes Drug delivery systems Ophthalmology |
| topic |
Síndrome de Sjögren Liposomes Sistemes d'alliberament de medicaments Oftalmologia Sjogren's syndrome Liposomes Drug delivery systems Ophthalmology |
| description |
Sjögren's syndrome is a chronic systemic autoimmune disease affecting from 0.2 to 3% of the general population. The current treatment for Sjögren's syndrome is aimed at controlling symptoms such as dry eyes and xerostomia. Systemic therapy with glucocorticoids or immunosuppressants is also used. Baricitinib is an immunosuppressant drug, specifically a Janus kinases 1 and 2 selective inhibitor. We propose ocular liposomal formulations loaded with baricitinib for the management of Sjögren's syndrome. The novelty of the work relies on the fact that, for the first time, baricitinib is intended to be used for topical delivery. Two liposomal formulations were prepared with different lipids: (i) L-α-phosphatidylcholine (Lα-PC) and (ii) a combination of lipids 1-palmitoyl-2-oleoyl-phosphatidylethanolamine: s1-Palmitoyl-2-oleoyl-sn-glycerol-3-phosphoglycerol (3:1, mol/mol) (POPE:POPG), and they were physicochemically characterized. The in vitro drug release and the ex vivo permeation through corneal and scleral tissues were also assessed. Finally, the tolerance of the formulations on the ocular tissues was evaluated by the HET-CAM technique, as well as through the histological analysis of the cornea and sclera and the cornea transparency. Both liposomes resulted in small, spherical shapes, with suitable physicochemical properties for the ocular administration. Lα-PC led to higher flux, permeation, and retention in the sclera, whereas POPE:POPG led to higher flux and permeation in the cornea. The formulations showed no irritant effects on the chorioallantoic membrane. Additionally, the liposomes did not affect the cornea transparency when they were applied, and the histological analysis did not reveal any structural alteration |
| publishDate |
2022 |
| dc.date.none.fl_str_mv |
2022 2022 2022 2022 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/2445/191490 |
| url |
https://hdl.handle.net/2445/191490 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics14091895 Pharmaceutics, 2022 https://doi.org/10.3390/pharmaceutics14091895 |
| dc.rights.none.fl_str_mv |
cc-by (c) Garrós, Núria et al., 2022 https://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
cc-by (c) Garrós, Núria et al., 2022 https://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
MDPI |
| publisher.none.fl_str_mv |
MDPI |
| dc.source.none.fl_str_mv |
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) reponame:Recercat. Dipósit de la Recerca de Catalunya instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| instname_str |
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| reponame_str |
Recercat. Dipósit de la Recerca de Catalunya |
| collection |
Recercat. Dipósit de la Recerca de Catalunya |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869415815274561536 |
| score |
15,812455 |